Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 43, Issue 3, 2018, Pages 269-280

  Mikov, Momir ^a   Đanić, Maja ^a   Pavlović, Nebojša ^a   Stanimirov, Bojan ^a   Goločorbin Kon, Svetlana ^a   Stankov, Karmen ^a   Al Salami, Hani ^b  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 MONOKETOCHOLIC ACID SODIUM SALT; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BILE ACID; CHOLIC ACID DERIVATIVE; FARNESOID X RECEPTOR; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; PROBIOTIC AGENT; SULFONYLUREA RECEPTOR 1; TAUROCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ANTIDIABETIC AGENT;

ALLOXAN-INDUCED DIABETES MELLITUS; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; COMMENSAL; DRUG ABSORPTION; DRUG POTENTIATION; DRUG TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE FLORA; MICROENCAPSULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RENAL PROTECTION; REVIEW; SUSTAINED DRUG RELEASE; ANIMAL;

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 1; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; PROBIOTICS;

EID: 85031946118     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-017-0441-y     Document Type: Review

References (113)

1. Mittermayer F, Caveney E, Oliveira CD, Gourgiotis L, Puri M, Tai LJ, et al. Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development. Curr Diabetes Rev. 2015;11(1):17–31.
2. Sena CM, Bento CF, Pereira P, Seiça R. Diabetes mellitus: new challenges and innovative therapies. EPMA J. 2010;1(1):138–63.
3. Al-Salami H, Kansara H, King J, Morar B, Jayathilaka B, Fawcett P, et al. Bile acids: a bitter sweet remedy for diabetes. NZ Pharm J. 2007;27:17–20.
4. Mikov M, Al-Salami H, Golocorbin-Kon S. Potentials and limitations of bile acids and probiotics in diabetes mellitus. In: Liu C, editor. Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments, 2011, InTech. https://www.intechopen.com/books/type-1-diabetes-complications-pathogenesis-and-alternative-treatments/potentials-and-limitations-of-bile-acids-and-probiotics-in-diabetes-mellitus. Accessed 12 June 2017.
5. Mikov M, Fawcett JP, Kuhajda K, Kevresan S. Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur J Drug Metab Pharmacokinet. 2006;31(3):237–51.
6. Mikov M, Fawcett JP. Chemistry, biosynthesis, analysis, chemical & metabolic transformations and pharmacology. Eur J Drug Metab Pharmacokinet. 2006;31(3):133–4.
7. Soyucen E, Gulcan A, Aktuglu-Zeybek AC, Onal H, Kiykim E, Aydin A. Differences in the gut microbiota of healthy children and those with type 1 diabetes. Pediatr Int. 2014;56(3):336–43.
8. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5(1):82–91.
9. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383(9922):1084–94.
10. McCall AL, Farhy LS. Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control. Minerva Endocrinol. 2013;38(2):145–63.
11. King AJF. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877–94.
12. Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017;13(7);385–399. doi:10.1038/nrendo.2017.39.
13. Soltesz G, Patterson CC, Dahlquist G. Worldwide childhood type 1 diabetes incidence–what can we learn from epidemiology? Pediatr Diabetes. 2007;8(Suppl 6):6–14.
14. Bruno G, Gruden G, Songini M. Incidence of type 1 diabetes in age groups above 15 years: facts, hypothesis and prospects for future epidemiologic research. Acta Diabetol. 2016;53(3):339–47.
15. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82.
16. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, obesity and type 2 diabetes mellitus. Rev Endocr Metab Disord. 2015;16(1):55–65.
17. Hameed S, Ellard S, Woodhead HJ, Neville KA, Walker JL, Craig ME, et al. Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children. Pediatr Diabetes. 2011;12(3 Pt 1):142–9.
18. Dabelea D, Pihoker C, Talton JW, D’Agostino RB Jr, Fujimoto W, Klingensmith GJ, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2011;34(7):1628–33.
19. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet. 2006;15(11):1793–800.
20. Remedi MS, Kurata HT, Scott A, Wunderlich FT, Rother E, Kleinridders A, et al. Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus. Cell Metab. 2009;9(2):140–51.
21. Denton JS, Jacobson DA. Channeling dysglycemia: ion-channel variations perturbing glucose homeostasis. Trends Endocrinol Metab. 2012;23(1):41–8.
22. Remedi MS, Thomas M, Nichols CG, Marshall BA. Sulfonylurea challenge test in subjects diagnosed with type 1 diabetes mellitus. Pediatr diabetes. 2017. doi:10.1111/pedi.12489.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62–7.
24. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27(4):269–73.
25. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012;9(1):6–22.
26. Schernthaner G. Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism. 2003;52(8 Suppl 1):29–34.
27. Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metab. 2012;14(Suppl 1):9–13.
28. Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and Pharmaceutical Profile of Gliclazide: a Review. J Appl Pharm Sci. 2011;1(9):11–9.
29. Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–8.
30. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract. 1991;14:S21–36.
31. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115(8):2047–58.
32. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467–77.
33. Sagen JV, Pearson ER, Johansen A, Spyer G, Sovik O, Pedersen O, et al. Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers. Diabet Med. 2005;22(4):406–9.
34. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol. 1998;31(5):950–6.
35. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(3):S368.
36. Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3(1):43–51.
37. Singh AK, Singh R. Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Rev Clin Pharmacol. 2016;9(6):839–51.
38. Bonner-Weir S, Sharma A. Are there pancreatic progenitor cells from which new islets form after birth? Nat Clin Pract Endocrinol Metab. 2006;2(5):240–1.
39. Del Guerra S, D’Aleo V, Lupi R, Masini M, Bugliani M, Boggi U, et al. Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide. Diabetes Metab. 2009;35(4):293–8.
40. Nakano N, Miyazawa N, Sakurai T, Kizaki T, Kimoto K, Takahashi K, et al. Gliclazide inhibits proliferation but stimulates differentiation of white and brown adipocytes. J Biochem. 2007;142(5):639–45.
41. Del Guerra S, Grupillo M, Masini M, Lupi R, Bugliani M, Torri S, et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev. 2007;23(3):234–8.
42. Szewczyk A. Intracellular targets for antidiabetic sulfonylureas and potassium channel openers. Biochem Pharmacol. 1997;54(9):961–5.
43. Beck-Nielsen H, Hother-Nielsen O, Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med. 1988;5(7):613–20.
44. Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress—a concise review. Saudi Pharm J. 2016;24(5):547–53.
45. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.
46. Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J. 2012;12(1):5–18.
47. West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000;17(3):171–80.
48. Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metab Clin Exp. 2000;49(10 Suppl 2):17–20.
49. Scott NA, Jennings PE, Brown J, Belch JJ. Gliclazide: a general free radical scavenger. Eur J Pharmacol. 1991;208(2):175–7.
50. Onozato ML, Tojo A, Goto A, Fujita T. Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int. 2004;65(3):951–60.
51. Desfaits AC, Serri O, Renier G. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metab Clin Exp. 1997;46(10):1150–6.
52. Stanimirov B, Stankov K, Mikov M. Pleiotropic functions of bile acids mediated by the farnesoid X receptor. Acta Gastroenterol Belg. 2012;75(4):389–98.
53. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010;8:e0005. doi:10.1621/nrs.08005.
54. Prawitt J. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep. 2011;11(3):160–6.
55. Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32(Suppl 2):S237–45.
56. Woodhams L, Al-Salami H. The roles of bile acids and applications of microencapsulation technology in treating type 1 diabetes mellitus. Ther Deliv. 2017;8(6):401–9.
57. Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 2008;33(2):101–6.
58. Miljkovic D, Kuhajda K, Mikov M, Kevresan S, Sabo A. Bile acids and their derivatives as glycoregulatory agents. Patents; 2000.
59. Stepanov V, Stankov K, Mikov M. The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res. 2013;33(4):213–23.
60. Stanimirov B, Stankov K, Mikov M. Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases. Hepatobiliary Pancreat Dis Int. 2015;14(1):18–33.
61. Staels B, Handelsman Y, Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep. 2010;10(1):70–7.
62. Stojancevic M, Stankov K, Mikov M. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol. 2012;26(9):631.
63. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50(10):1955–66.
64. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010;28(1):220–4.
65. Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta. 2010;1802(3):363–72.
66. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem. 2004;279(22):23158–65.
67. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51(4):771–84.
68. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap–bile acids in metabolic control. Nat Rev Endocrinol. 2014;10(8):488–98.
69. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 2004;53(4):890–8.
70. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–77.
71. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484–9.
72. Williams DL. Neural integration of satiation and food reward: role of GLP-1 and orexin pathways. Physiol Behav. 2014;136:194–9.
73. Parker JA, McCullough KA, Field BC, Minnion JS, Martin NM, Ghatei MA, et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes. 2013;37(10):1391–8.
74. Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis. 2014;46(4):302–12.
75. Kumar DP, Rajagopal S, Mahavadi S, Mirshahi F, Grider JR, Murthy KS, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells. Biochem Biophys Res Commun. 2012;427(3):600–5.
76. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci. 2009;30(11):570–80.
77. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329(1):386–90.
78. Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol. 2016;7:1081.
79. Stojancevic M, Bojic G, Salami HA, Mikov M. The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr Issues Mol Biol. 2013;16(2):55–68.
80. Kosiewicz MM, Zirnheld AL, Alard P. Gut microbiota, immunity, and disease: a complex relationship. Front. Microbiol. 2011;2:180.
81. Lerner A, Matthias T. GUT-the Trojan horse in remote organs’ autoimmunity. J Clin Cell Immunol. 2016;7(401):10–4172.
82. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol. 2016;12(3):154–67.
83. Vaarala O. Human intestinal microbiota and type 1 diabetes. Curr Diab Rep. 2013;13(5):601–7.
84. Joint FAO/WHO Working Group. Guidelines for the evaluation of probiotics in food. London, Ontario, Canada; 2002. http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed 20 June 2017.
85. Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011;6(3):209–40.
86. Stojančević M, Bojić G, Al-Salami H, Mikov M. The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr Issues Mol Biol. 2013;4(16):2.
87. Kleerebezem M, Vaughan EE. Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Annu Rev Physiol. 2009;63:269–90.
88. Soccol CR, Vandenberghe LPdS, Spier MR, Medeiros ABP, Yamaguishi CT, Lindner JDD, et al. The potential of probiotics: a review. Food Technol Biotechnol. 2010;48(4):413–34.
89. Fallucca F, Sciullo E, Maldonato A. Combined therapy with insulin and sulfonylurea for the treatment of new-onset insulin-dependent diabetes mellitus. Horm Metab Res. 1996;28(02):86–8.
90. Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 2008;30(2):107–13.
91. Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2012;37(2):99–108.
92. Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf. 2008;1(1):35–41.
93. Lukivskaya O, Patsenker E, Buko VU. Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci. 2007;80(26):2397–402.
94. Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899–905.
95. Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. Int J Clin Endocrinol Metab. 2013;98(4):E718–22.
96. Chen G, Yang L, Zhang H, Tucker IG, Fawcett JP. Effect of ketocholate derivatives on methotrexate uptake in Caco-2 cell monolayers. Int J Pharm. 2012;433(1):89–93.
97. Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, et al. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet. 2007;32(1):7–12.
98. Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 2008;33(3):137–42.
99. Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Devel Ther. 2014;8:1003–12.
100. Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151–6.
101. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015;20(6):702–9.
102. Mathavan S, Chen-Tan N, Arfuso F, Al-Salami H. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of type-1 diabetes. Drug Deliv. 2016;23(8):2869–80.
103. Golocorbin-Kon S, Calasan J, Milijasevic B, Vukmirovic S, Lalic-Popovic M, Mikov M et al. High-loading dose of microencapsulated gliclazide formulation exerted a hypoglycaemic effect on type 1 diabetic rats and incorporation of a primary deconjugated bile acid, diminished the hypoglycaemic antidiabetic effect. Eur J Drug Metab Pharmacokinet. 2017. doi:10.1007/s13318-017-0415-0.
104. Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J of Nanomedicine. 2011;6:1155–66.
105. Kuhajda K, Kevrešan S, Mikov M, Sabo A, Miljkovic D. 3α, 7α-dihydroxy-12-oxo-5β-cholanate as enhancer of insulin nasal absorption in rats. Arch Toxicol Kinet Xenobiot Metabol. 1997;5:359–61.
106. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 2014;9(2):150–7.
107. Djanic M, Pavlovic N, Stanimirov B, Stojancevic T, Golocorbin-Kon S, Bojic G, et al. Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria. Eur Rev Med Pharmacol Sci. 2016;20(3):553–60.
108. Stojančević M, Pavlović N, Goločorbin-Kon S, Mikov M. Application of bile acids in drug formulation and delivery. Front Life Sci. 2013;7(3–4):112–22.
109. Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 2008;60(4):532.
110. Lalić-Popović M, Vasović V, Milijašević B, Goločorbin-Kon S, Al-Salami H, Mikov M. Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabetes Res. 2013;2013:598603. doi:10.1155/2013/598603.
111. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15(14):1677–89.
112. Klaassen CD, Cui JY. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos. 2015;43(10):1505–21.
113. Yang L, Zhang H, Mikov M, Tucker IG. Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer. Mol Pharm. 2009;6(2):448–56.